Concepedia

Jill Bowman

JB

4

Publications

330

Citations

4

H-Index

2012

Active since

Affiliations

Incyte (United States)(Current)

University of Chicago

Jill Bowman is an author at Incyte (United States) specializing in medicine, cancer therapeutics, and radiation oncology.

ORCID

Top concepts

Publications per year

2012–2014

4

Publications

4

Oclacitinib (<scp>APOQUEL</scp><sup>®</sup>) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Andrea J. Gonzales, Jill Bowman, Gregory J. Fici et al. · Journal of Veterinary Pharmacology and Therapeutics · 2014 · 236 citations · Full text

Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.

Geoffrey T. Gibney, Omid Hamid, Tara C. Gangadhar et al. · Journal of Clinical Oncology · 2014 · 52 citations

, , +21

Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients.

Robert Newton, Peggy Scherle, Kevin Bowman et al. · Journal of Clinical Oncology · 2012 · 29 citations

, , +22

Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study

Naresh Punwani, Swamy Yeleswaram, Xuejun Chen et al. · Clinical Pharmacology in Drug Development · 2013 · 13 citations

, , +26

Rows per page

1–4 of 4